Genomic sequencing has led to vastly increased opportunities for population-level genomic studies to discover novel genomic alterations associated with both Mendelian and complex phenotypes. To translate genomic findings clinically, several healthcare institutions have worked collaboratively or individually to initiate precision medicine programs. These precision medicine programs involve designing and implementing patient enrollment systems, tracking electronic health records, building biobank repositories, and matching genomic results with actionable therapies.
Cancer is comprised of a multitude of distinct genetic diseases and new therapies are increasingly tailored to attack critical genetic susceptibilities using genetic profiling. In addition to cancer, the scope of this Research Topic covers other diseases that can be impacted by precision therapies.
This Research Topic addresses but is not limited to the current challenges regarding precision oncology, including:
(1) The limited number of FDA-approved drugs with genomic-guide actionable therapies.
(2) The impact of the patient and tumor microenvironment on cancer genetic evolution and heterogeneity
(3) Population genetic heterogeneity and cancer disparities
(4) Genomic and clinical data harmonization and data sharing across different healthcare enterprises.
(5) Cost-effectiveness of genetic testing for health economics.
This Research Topic intends to draw biomedical academics’ attention and provide proofs of concept and areas of opportunity in order to significantly increase the likelihood of molecular-directed therapies. These more tailored treatment approaches are poised to enhance efficacy and limit toxicity.
Genomic sequencing has led to vastly increased opportunities for population-level genomic studies to discover novel genomic alterations associated with both Mendelian and complex phenotypes. To translate genomic findings clinically, several healthcare institutions have worked collaboratively or individually to initiate precision medicine programs. These precision medicine programs involve designing and implementing patient enrollment systems, tracking electronic health records, building biobank repositories, and matching genomic results with actionable therapies.
Cancer is comprised of a multitude of distinct genetic diseases and new therapies are increasingly tailored to attack critical genetic susceptibilities using genetic profiling. In addition to cancer, the scope of this Research Topic covers other diseases that can be impacted by precision therapies.
This Research Topic addresses but is not limited to the current challenges regarding precision oncology, including:
(1) The limited number of FDA-approved drugs with genomic-guide actionable therapies.
(2) The impact of the patient and tumor microenvironment on cancer genetic evolution and heterogeneity
(3) Population genetic heterogeneity and cancer disparities
(4) Genomic and clinical data harmonization and data sharing across different healthcare enterprises.
(5) Cost-effectiveness of genetic testing for health economics.
This Research Topic intends to draw biomedical academics’ attention and provide proofs of concept and areas of opportunity in order to significantly increase the likelihood of molecular-directed therapies. These more tailored treatment approaches are poised to enhance efficacy and limit toxicity.